Lichenoid eruption due to chlorpropamide.
نویسندگان
چکیده
منابع مشابه
Lichenoid drug eruption due to eprosartan/hydrochlorothiacide
We report a case of a 66-year-old male who developed an itchy eruption while taking an antihypertonic drug containing eprosartan and hydrochlorothiacide after sun exposure. The lesions resembled a lichenoid appearance that was confirmed by the histological study. There are few reports in the literature of lichenoid reactions to these compounds, so we review the characteristics of themselves as ...
متن کاملHypertrophic lichenoid eruption due to furosemide.
© 2010 The Authors. doi: 10.2340/00015555-0754 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 Sir, Lichenoid drug eruption (LDE) following furosemide intake has been reported once in the literature (1). Several cases of bullous eruption (2) and generalized exanthematic pustulosis (3) caused by this drug have also been describ ed. We report here the case of a patient who d...
متن کاملHyperinsulinaemic hypoglycaemia due to chlorpropamide-induced nesidioblastosis.
A 25 year old woman suffering from recurrent attacks of hypoglycaemia underwent a laparotomy for suspected insulinoma. No tumour was found, but histology showed islet cell hyperplasia and nesidioblastosis. Although these changes have been reported as a cause of hypoglycaemia in infants, they are only rarely the cause of hypoglycaemia in adults; in the present case they were found to be the resu...
متن کاملLichenoid drug eruption associated with Bendamustine
A 65-year-old man had relapsed follicular lymphoma. When he suffered a fifth relapse, he received a regimen containing bendamustine and rituximab (BR). Four weeks later, he presented with systemic erythema, swelling and bullous lesions of lips, the oral cavity, andnasal mucosa and eye pain. He could not open his mouth and had severe pain. Steven–Johnson syndrome/toxic epidermal necrolysis was d...
متن کاملImatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1968
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.1.5584.100